Suchen
Shattuck Labs Inc
STTKZur Watchlist hinzufügen
6.310USD
-0.050-0.79%
Handelsschluss 09-24 16:00（ET）
570.23MMarktkapitalisierung
VerlustKGV TTM
Über Shattuck Labs Inc Unternehmen
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc Profil
BörsenkürzelSTTK
Name des UnternehmensShattuck Labs Inc
IPO-datumOct 09, 2020
CEOSchreiber (Taylor)
Anzahl der mitarbeiter44
WertpapierartOrdinary Share
GeschäftsjahresendeOct 09
Addresse500 W. 5Th Street
StadtAUSTIN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl78701
Telefon15129004690
Websitehttps://www.shattucklabs.com/
BörsenkürzelSTTK
IPO-datumOct 09, 2020
CEOSchreiber (Taylor)
Führungskräfte von Shattuck Labs Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Ms. Casi DeYoung
Ms. Casi DeYoung
Chief Business Officer
Chief Business Officer
73.48K
-10.87%
Ms. Casi DeYoung
Ms. Casi DeYoung
Chief Business Officer
Chief Business Officer
73.48K
-10.87%
Ms. Casi DeYoung
Ms. Casi DeYoung
Chief Business Officer
Chief Business Officer
73.48K
-10.87%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
122.22K
+20.95%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
93.37K
+12.68%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Shattuck Labs Inc?
Die fünf größten Anteilseigner von Shattuck Labs Inc sind: Dr. Taylor Schreiber, M.D., Ph.D.
Wie viele Institutionen halten Anteile an Shattuck Labs Inc (STTK)?
Mit Stand vom 2026Q1 halten 189 Institutionen Anteile an Shattuck Labs Inc, mit einem Gesamtmarktwert von etwa 50.41M, was 65.78% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 9741871.00 gestiegen.